Rezulin (troglitazone) is now approved for INITIAL therapy of type 2 diabetes
September 1997
Rezulin (troglitazone) is now approved for INITIAL therapy of type 2 diabetes...and for use with a sulfonylurea. Initially, it was approved only for patients poorly controlled on insulin.
For initial therapy, Rezulin works about as well as metformin (Glucophage) or a sulfonylurea. It lowers blood sugar about 50 mg/dL...and reduces glycosylated hemoglobin (HbA1c) about 1.5%.
Rezulin helps lower insulin resistance. It also seems to improve blood pressure and lipids.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote